Gynecologic

« Previous 12 Next »
Viewing Page 1 of 2 | Showing Results 1 - 10 of 18

DFC CL-OVA-P01-00-US (Aivita) - Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy

Inclusion Criteria:ECOG performance status of 0-1 (Karnofsky score of 70-100%)Successful establishment of an autologous epithelial ovarian,...

Richard Friedman, M.D.
  • Disney Family Cancer Center (DFCC)
  • Providence Los Angeles Research Center

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)

Inclusion Criteria:•Has persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix...

Melissa Hardesty MD
  • Alaska Research
  • Alaska Women's Cancer Care
  • Providence Alaska Medical Center

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer.

This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin, works compared with paclitaxel and carboplatin...

Dan Zuckerman, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

ADXS001-02 (GOG-3009): Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV

High-risk locally advanced carcinoma of the cervix (HRLACC) following concurrent chemotherapy and radiation therapy. This is a group of patients...

Tariq Mahmood, M.D.
  • St. Joseph Hospital of Orange
  • xSJH Southern California

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors.Inclusion...

Josh Press, M.D.
  • Swedish Medical Center

The nCYT Study: A Powered Study to Evaluate the Sensitivity and Specificity of Cytological Evaluation of Fallopian Tube Samples Collected by the MAKO 7 in Determining the Presence of Malignancy

Inclusion Criteria:• Subject is medically cleared for surgery• Subject is scheduled to undergo salpingo-oophorectomy or salpingectomy for a pelvic...

Charles Drescher, M.D.
  • Swedish Medical Center

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy

This randomized phase III trial is studying chemotherapy and pelvic radiation therapy to see how well they work when given with or without...

Benjamin Bridges , M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, State I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy.

This randomized phase III trial studies radiation therapy with chemotherapy to see how well it works compared to radiation therapy alone in...

Benjamin Bridges , M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

« Previous 12 Next »
Viewing Page 1 of 2 | Showing Results 1 - 10 of 18